Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Algazi et al.
Clinical Cancer Research
June 2020
Authors and Affiliates
Alain P Algazi # 1, Christopher G Twitty # 2, Katy K Tsai 1, Mai Le 3, Robert Pierce 4, Erica Browning 2, Reneta Hermiz 2, David A Canton 2, Donna Bannavong 2, Arielle Oglesby 1, Murray Francisco 2, Lawrence Fong 1, Mikael J Pittet 5, Sean P Arlauckas 6, Christopher Garris 7, Lauren P Levine 1, Carlos Bifulco 8, Carmen Ballesteros-Merino 8, Shailender Bhatia 4, Sharron Gargosky 2, Robert H I Andtbacka 9, Bernard A Fox 8, Michael D Rosenblum 1, Adil I Daud 10; 1University of California, San Francisco, San Francisco, California. 2OncoSec Medical Incorporated, Pennington, New Jersey. 3DR HOPE LLC, Seattle, Washington. 4Fred Hutchinson Cancer Research Center, Seattle, Washington. 5Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 7Rockefeller University, New York, New York. 8Earle A. Chiles Research Institute, Portland, Oregon. 9Huntsman Cancer Institute, Salt Lake City, Utah. 10University of California, San Francisco, San Francisco, California. Adil.daud@ucsf.edu. #Contributed equally.